Abstract: Objective To evaluate the efficacy of adalimumab in improving the quality of life of adult patients with active ankylosing spondylitis （AS）. Methods This was a post-hoc study of the randomized,double-blind controlled clinical trial of adalimumab and placebo in AS patients. In this clinical trial,AS patients were randomly divided into the 12-week adalimumab and placebo groups according to the proportion of 2∶1. In the adalimumab group,AS patients were treated with adalimumab at a single dose of 40 mg,once every two weeks. The SF-36 Quality of Life Questionnaire was distributed to patients to self-evaluate health status before and at the 12th week after medication,respectively. Results AS patients in the adalimumab group obtained significant improvement in the scores of physiological functioning,bodily pain and social functioning compared with their counterparts in the placebo group （all P < 0.05）. In the adalimumab group,the scores of physical functioning,role-playing physical functioning,bodily pain,overall health,vitality and social functioning after 12-week medication therapy were improved compared with the baseline scores（all P < 0.05）. Conclusion Adalimumab is beneficial to enhancing the quality of life of adult patients with active AS.